98%
921
2 minutes
20
Polymeric vascular implants with ideal mechanical properties and biocompatibility are essential for dilating blood vessels and reducing the risk of secondary implant diseases. However, traditional polymer materials are still limited for vascular stents by diminished radial support post-expansion and inadequate surface modification techniques. Herein, we synthesized zwitterionic polyurethanes (ZPUs) featuring hydrophilic side chains derived from betaine sulfonate and full-hard main chains. These ZPUs demonstrate a remarkable increase in modulus during shape recovery in 37 °C warm water, ensuring that the stent remains soft during implantation for easy delivery, but becomes stiff once positioned at the lesion site to provide adequate radial support. The distinctive architecture promotes the migration of hydrophilic side chains to the surface upon hydration, establishing a "core-shell structure" with a hard interior and a highly hydrophilic surface that enhances antithrombotic properties, mitigates inflammation, and curbs intimal hyperplasia. Consequently, ZPUE20 stent showed significantly better blood flow patency than traditional PLA stent in carotid artery implantation for at least 3 months, ensuring the long-term biological safety of implantation. Compared to surface modification of bare stents, ZPU stents avoid the complex and unstable surface modifications. All in all, ZPUs represent a promising material for vascular implants, markedly improving both mechanical performance and biocompatibility.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biomaterials.2025.123394 | DOI Listing |
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
JACC Cardiovasc Interv
September 2025
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: Previous trials have demonstrated increased 5-year risks for adverse clinical events after coronary artery implantation of poly-l-lactic acid-based bioresorbable scaffolds (BRS) compared with cobalt chromium (CoCr) everolimus-eluting stents (EES).
Objectives: The aim of this study was to evaluate the 5-year clinical outcomes of the novel sirolimus-eluting NeoVas BRS compared with CoCr EES.
Methods: A total of 560 patients with single de novo native coronary artery lesions with reference vessel diameter 2.
JACC Cardiovasc Interv
September 2025
CVPath Institute, Gaithersburg, Maryland, USA; University of Maryland, School of Medicine, Baltimore, Maryland, USA. Electronic address:
Background: Effective modification of heavily calcified coronary lesions is critical for successful percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL), cutting balloons (CBs), and ultra-high-pressure balloons (UHBs) are used commonly, yet data comparing their effectiveness and safety for calcified lesion modification remain unavailable.
Objectives: The aim of this study was to compare the effects of IVL, a CB, and a UHB on calcified coronary lesions in human cadaveric arteries, focusing on calcium fracture formation and vascular injury.
J Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.
Ann Vasc Surg
September 2025
Division of Vascular Surgery, 1(st) Surgical Department, Faculty of Health Sciences, Aristotle University, Papageorgiou General Hospital, Thessaloniki, Greece.
Introduction: Nitides™ (Alvimedica, Istanbul, Turkey) is a novel polymer-free stent, which elutes Amphilimus™; a combination of sirolimus and long chain fatty acids. Aim of this prospective single-center study is to assess the efficacy and 12-months outcomes of patients with femoropopliteal arterial disease, who underwent successful angioplasty with implantation of Amphilimus™-eluting stents Nitides™.
Methods: Patients with peripheral arterial disease who underwent angioplasty of the femoropopliteal segment with DES Nitides™ from August 2021 to February 2024 were included in the study.